Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, octubre 19
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Vera Therapeutics Inc
VERA
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$27.88
-0.69
-2.42%
Últ. Act.: Oct 19, 7:18 AM
$28.00
-0.57
-2%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Vera Therapeutics Financials
Vera Therapeutics (VERA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from
Benzinga Newsdesk
PRO
Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.31) by 6.19 percent. This is a 93.06 percent decrease over losses of $(0.72) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.16) by 8.71 percent. This is a 48.24 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q2 2025 EPS $(1.20) Misses $(0.83) Estimate, Vera Reported $556.8M In Cash, Cash Equivalents, And Marketable Securities
Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept anticipated in 2026 and beyond
Benzinga Newsdesk
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results
Avi Kapoor
